How to Buy Alumis Stock
Alumis Inc
Alumis Inc. is a biopharmaceutical firm currently in the clinical trial phase, dedicated to advancing and marketing therapeutic solutions for a range of autoimmune conditions.
Alumis stock last closed at $22.32, down 2.96% from the previous day, and has increased 613.1% in one year. It has overperformed other stocks in the Biotechnology industry by 6.85 percentage points. Alumis stock is currently +708.7% from its 52-week low of $2.76, and -27.06% from its 52-week high of $30.60.
At the moment, there are 127.49M shares of ALMS outstanding. The market value of ALMS is $2.85B. In the past 24 hours, 881,000 ALMS shares were traded.
How to Buy Alumis Stock
Not sure how to invest in Alumis stock? Here's how.
- Choose where to buy Alumis stock: You need to decide on an online brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you choose where to buy Alumis stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Put funds into your brokerage account: Pick your payment method and add your details.
- Analyze Alumis stock: The Alumis ticker symbol is ALMS. Is Alumis stock a good investment? Should you buy shares of ALMS? How do ALMS's underlying business fundamentals look? Do top analysts think Alumis is a good buy? Why has ALMS's stock price moved recently? (Hint: Our stock analysis website can help you figure out if ALMS is a good stock to buy).
- Place your ALMS trade: Decide if you will purchase ALMS shares at the current market price or use a limit order to purchase ALMS stock at a specific price.
- Keep an eye on your ALMS position: Create a watchlist to monitor your investment in Alumis shares.
Step 1: Choose where to buy Alumis stock
You need a brokerage account in order to access the NASDAQ market and buy ALMS stock.
Our recommended brokerage: eToro
In our opinion, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Technology to Real Estate, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected your brokerage, it's time to fill out some personal info so you are able to buy ALMS today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to create your new brokerage account.
- Send your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have created your account on apps for stocks, you need to deposit funds:
Check out the walkthrough below if you need help depositing funds into your new brokerage account.
Step 4: Analyze Alumis stock
After you have figured out the best place to buy Alumis stock, it's absolutely critical to analyze their stock prior to investing, so you truly comprehend the risk and opportunity.
Overview of key ALMS info
Alumis Due Diligence Score
WallStreetZen was created to help part-time investors perform more accurate fundamental analysis in less time.
You can view all of the due diligence checks on ALMS's stock page.
How is ALMS stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge ALMS's true value.
Using relative valuations methods:
- ALMS could be overvalued based on its P/B ratio of 5.02x, relative to Biotechnology industry P/B ratio of 4.86x
You can do additional valuation research on ALMS's stock here.
ALMS Financials at a glance
Signs that ALMS is financially healthy:
- ALMS has a low debt to equity ratio of 0.18.
- There are more short-term assets than long-term liabilities on the ALMS balance sheet.
- There are more short-term assets than short-term liabilities on the ALMS balance sheet.
- ALMS has cash burn of 377030000. It has sufficient cash and short-term investments to cover this for at least one year.
- ALMS has $523.03M in cash and short term investments. This is sufficient to cover its annual cash burn of $377.03M.
Signs that ALMS is not financially healthy:
- ALMS profit margin has gone down from -1,974.5% to -2,825.7% in the past year.
Is it a good time to buy Alumis stock, according to analysts?
Out of 9 Wall Street analysts who research ALMS, the consensus analyst rating on Alumis is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent ALMS Analyst Recommendations
Terence Flynn, a top 7% analyst from Morgan Stanley maintains ALMS with a strong buy rating and raises their ALMS price target from $33.00 to $38.00, on Mar 20, 2026.
Morgan Stanley's Terence Flynn raised their price target on Alumis (NASDAQ: ALMS) by 15.2% from $33 to $38 on 2026/03/20. The analyst maintained their Strong Buy rating on the stock.
Alumis reported its Q4 and FY 2025 earnings.
Flynn described the quarter's EPS number as "a non-event."
Instead, the analyst argued, the full presentation of envudeucitinib's Phase 3 psoriasis results at AAD on 2026/03/28 will be the stock's price's next upside catalyst.
Separately, in anticipation of the Phase 2b LUMUS data coming in Q3, Flynn increased their projections for envudeucitinib in SLE.
Earnings Report
For FY 2025, Alumis reported:
- Net loss of $243.33M, compared to FY 2024's net loss of $294.23M.
- Revenue of $24.05M.
Management did not provide EPS and revenue guidance in its press release.
President & CEO Martin Babler commented: “Alumis concluded a pivotal year marked by strong execution and the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis, underscoring the promise of TYK2 inhibition and envudeucitinib’s highly differentiated clinical profile.
“By maximally inhibiting TYK2 to block both IL-23 and IL-17 pathways, envudeucitinib delivered comprehensive disease control with rapid onset of action, high rates of skin clearance, and meaningful symptom improvements in our Phase 3 ONWARD program that reinforce our conviction in envudeucitinib’s potential to transform the psoriasis treatment landscape.
“We look forward to our clinical topline readout for our potentially pivotal LUMUS Phase 2b trial in SLE, anticipated in the third quarter of this year.
“Importantly, the results of both psoriasis and SLE will potentially unlock envudeucitinib’s pipeline‑in‑a‑pill opportunity to leverage maximal TYK2 inhibition across multiple immune‑mediated diseases.
“Alumis is evaluating additional indications for our TYK2 inhibitors as part of a unified franchise development strategy that we plan to announce in the second quarter of 2026.”
Christopher Raymond, a bottom 11% analyst from Raymond James initiates coverage on ALMS with a strong buy rating and announces their ALMS price target of $46.00, on Mar 11, 2026.
Alex Thompson, a top 10% analyst from Stifel Nicolaus initiates coverage on ALMS with a strong buy rating and announces their ALMS price target of $44.00, on Feb 25, 2026.
Thomas Smith, a top 12% analyst from Leerink Partners maintains ALMS with a buy rating and raises their ALMS price target from $20.00 to $32.00, on Jan 7, 2026.
You can dig deeper into what analysts are saying on the Alumis stock forecast page.
Metrics for Advanced ALMS Traders
Is ALMS Growing Revenue?
Last year, ALMS revenue was $8.40M. In the past one years, ALMS's revenue has gone up by -51.68% per year. This was slower than the Biotechnology industry average of 32.16%.
You can research ALMS's earnings and revenue performance here.
What are ALMS executives and large shareholders up to?
Over the past year, insiders at ALMS have bought more shares than they have sold.
Jorn Drappa, Chief Medical Officer of ALMS, was the latest ALMS insider to buy. They bought $100,042.28 worth of ALMS shares on May 22, 2026.
Research more about who owns ALMS stock here.
Does ALMS stock generate passive income?
No, Alumis doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your ALMS trade
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly sufficient. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a given price limit, use a limit order.
Press the Open Trade button and your broker will execute your order.
If you want additional help investing in stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your ALMS position
Now that you own some shares in ALMS, you'll want to stay up-to-date on your shares.
Start a watchlist to get notified of the latest news about your ALMS stock.
ALMS Feed
How to Buy Stock in Alumis
To reiterate, here are the 6 steps to buy Alumis stock:
- Choose where to buy Alumis stock
- Open a brokerage account
- Put funds into your brokerage account
- Analyze Alumis stock
- Place your ALMS trade
- Keep an eye on your ALMS position
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get the latest news on your new investment in Alumis, get started below.
Other Content You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.